Penny stocks, especially in the early-stage biotech sector, often tend to be volatile and highly risky, but they also offer the potential for massive rewards. One such company is BioXcel Therapeutics (BTAI), which stands out right now for its late-stage pipeline progress, rising market potential, and approaching FDA milestone, making it a top penny stock to keep an eye on for 2026.
